Therapeutic potential of target of rapamycin inhibitors

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 551-564

  Easton, John B ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cancer; Immunosuppression; Mammalian target of rapamycin (mTOR) inhibition; Rapamycin; Transplantation

Indexed keywords

ABT 578; ADENOSINE TRIPHOSPHATE; ALPHA INTEGRIN; AMINO ACID; AP 23481; AP 23573; AZATHIOPRINE; BETA INTEGRIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; GROWTH FACTOR; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOSUPPRESSIVE AGENT; INITIATION FACTOR; INTEGRIN LINKED KINASE; ORNITHINE DECARBOXYLASE; PACLITAXEL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ANGIOGENESIS; APOPTOSIS; CANCER; CARDIAC ALLOGRAFT VASCULOPATHY; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG ELUTING STENT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY ALLOGRAFT REJECTION; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTERIAL OCCLUSIVE DISEASES; CELL DIVISION; CLINICAL TRIALS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; SIROLIMUS; STENTS; WOUND HEALING;

EID: 11144343679     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.551     Document Type: Review

References (123)

1. HEITMAN J, MOVVA NR, HALL MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 253 905-909.
2. KOLTIN Y, FAUCETTE L, BERGSMA DJ et al.: Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol. Cell. Biol. (1991) 11:1718-1723.
3. HELLIWELL SB, WAGNER P, KUNZ J, DEUTER-REINHARD M, HENRIQUEZ R, HALL MN: TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol. Biol. Cell (1994) 5:105-118.
4. KUNZ J, SCHNEIDER U, HOWALD I, SCHMIDT A, HALL MN: HEAT repeats mediate plasma membrane localization of Tor2p in yeast. J. Biol. Chem. (2000) 275:37011-37020.
5. POWERS T, DILOVA I, CHEN CY, WEDAMAN K: Yeast TOR signaling: a mechanism for metabolic regulation. Curr. Top. Microbiol. Immunol. (2004) 279:39-51.
6. KAMADA Y, FUNAKOSHI T, SHINTANI T, NAGANO K, OHSUMI M, OHSUMI Y: Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J. Cell Biol. (2000) 150:1507-1513.
7. 1-arresting rapamycin-receptor complex. Nature (1994) 369:756-758.
8. SABATINI DM, ERDJUMENT-BROMAGE H, LUI M, TEMPST P, SNYDER SH: RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell (1994) 78 35-43.
9. SABERS CJ, MARTIN MM, BRUNN GJ et al.: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. (1995) 270:815-822.
10. KEITH CT, SCHREIBER SL: PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science (1995) 270 50-51.
11. ABRAHAM RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. (2001) 15:2177-2196.
12. BOSOTTI R, ISACCHI A, SONNHAMMER EL: FAT: a novel domain in PIK-related kinases. Trends Biochem. Sci. (2000) 25:225-227.
13. CHEN J, ZHENG XF, BROWN EJ, SCHREIBER SL: Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA (1995) 92 4947-4951.
14. CHOI J, CHEN J, SCHREIBER SL, CLARDY J: Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 273:239-242.
15. SCOTT PH, BRUNN GJ, KOHN AD, ROTH RA, LAWRENCE JC Jr: Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA (1998) 95:7772-7777.
16. NAVE B T, OUWENS M, WITHERS DJ, ALESSI DR, SHEPHERD PR: Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. (1999) 344(Pt 2):427-431.
17. SEKULIC A, HUDSON CC, HOMME JL et al.: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. (2000) 60:3504-3513.
18. GINGRAS AC, KENNEDY SG, O'LEARY MA, SONENBERG N, HAY N: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. (1998) 12:502-513.
19. CHUNG J, GRAMMER TC, LEMON KP, KAZLAUSKAS A, BLENIS J: PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature (1994) 370:71-75.
20. ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:203-212.
21. UEKI K, ALGENSTAEDT P, MAUVAIS-JARVIS F, KAHN CR: Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. Mol. Cell. Biol. (2000) 20:8035-8046.
22. WHITMAN M, DOWNES CP, KEELER M, KELLER T, CANTLEY L: Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature (1988) 332:644-646.
23. CHAN TO, RITTENHOUSE SE, TSICHLIS PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Ann. Rev. Biochem. (1999) 68:965-1014.
24. DELCOMMENNE M, TAN C, GRAY V, RUE L, WOODGETT J, DEDHAR S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA (1998) 95:11211-11216.
25. PERSAD S, ATTWELL S, GRAY V et al.: Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. (2001) 276:27462-27469.
26. FENG J, PARK J, CRON P, HESS D, HEMMINGS BA: Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. (2004) 279:41189-41196.
27. INOKI K, LI Y, ZHU T, WU J, GUAN KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. (2002) 4:648-657.
28. POTTER CJ, PEDRAZA LG, XU T: Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. (2002) 4:658-665.
29. MANNING BD, TEE AR, LOGSDON MN, BLENIS J, CANTLEY LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. (2002) 10:151-162.
30. TEE AR, MANNING BD, ROUX PP, CANTLEY LC, BLENIS J: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. (2003) 13:1259-1268.
31. ZHANG Y, GAO Y, SAUCEDO LJ, RU B, EDGAR BA, PAN D: Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell. Biol. (2003) 5:578-581.
32. SAUCEDO LJ, GAO Y, CHIARELLI DA, LI L, PAN D, EDGAR BA: Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell. Biol. (2003) 5:566-571.
33. STOCKER H, RADIMERSKI T, SCHINDELHOLZ B et al.: Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell. Biol. (2003) 5:559-565.
34. INOKI K, LI Y, XU T, GUAN KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. (2003) 17:1829-1834.
35. BRUNN GJ, HUDSON CC, SEKULIC A et al.: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 277:99-101.
36. BURNETT PE, BARROW RK, COHEN NA, SNYDER SH, SABATINI DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA (1998) 95:1432-1437.
37. SCHALM SS, BLENIS J: Identification of a conserved motif required for mTOR signaling. Curr. Biol. (2002) 12:632-639.
38. HARA K, MARUKI Y, LONG X et al.: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 110:177-189.
39. KIM DH, SARBASSOV DD, ALI S M et al.: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 110:163-175.
40. SCHALM SS, FINGAR DC, SABATINI DM, BLENIS J: TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. (2003) 13:797-806.
41. NOJIMA H, TOKUNAGA C, EGUCHI S et al.: The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. (2003) 278:15461-15464.
42. KIM DH, SARBASSOV DOS D, ALI SM et al.: GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell. (2003) 11:895-904.
43. MADER S, LEE H, PAUSE A, SONENBERG N: The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol. Cell. Biol. (1995) 15:4990-4997.
44. PAUSE A, BELSHAM GJ, GINGRAS AC et al.: Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature (1994) 371:762-767.
45. ROSENWALD IB, KASPAR R, ROUSSEAU D et al.: Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. (1995) 270:21176-21180.
46. HASHEMOLHOSSEINI S, NAGAMINE Y, MORLEY SJ, DESRIVIERES S, MERCEP L, FERRARI S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. (1998) 273:14424-14429.
47. SHANTZ LM, PEGG AE: Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. (1994) 54:2313-2316.
48. ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. (2000) 60:1541-1545.
49. JEFFERIES HB, FUMAGALLI S, DENNIS PB, REINHARD C, PEARSON RB, THOMAS G: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k EMBO J. (1997) 16:3693-704.
50. TERADA N, PATEL HR, TAKASE K, KOHNO K, NAIRN AC, GELFAND EW: Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA (1994) 91:11477-11481.
51. JEFFERIES HB, REINHARD C, KOZMA SC, THOMAS G: Rapamycin selectively represses translation of the 'polypyrimidine tract' mRNA family. Proc. Natl. Acad. Sci. USA (1994) 91:4441-4445.
52. GINGRAS AC, RAUGHT B, SONENBERG N: mTOR signaling to translation. Curr. Top. Microbiol. Immunol. (2004) 279 169-197.
53. TANG H, HORNSTEIN E, STOLOVICH M et al.: Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol. (2001) 21:8671-8683.
54. PENDE M, UM SH, MIEULET V et al.: S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′ -terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. (2004) 24 3112-3124.
55. RAUGHT B, PEIRETTI F, GINGRAS AC et al.: Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. (2004) 23:1761-1769.
56. BROWNE GJ, PROUD CG: A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol. Cell. Biol. (2004) 24 2986-2997.
57. NOURSE J, FIRPO E, FLANAGAN WM et al.: Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 372:570-573.
58. BARATA JT, CARDOSO AA, NADLER LM, BOUSSIOTIS VA: Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood (2001) 98 1524-1531.
59. JIANG H, COLEMAN J, MISKIMINS R, MISKIMINS WK: Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int. (2003) 3:2.
60. WOLTMAN AM, VAN DER KOOIJ SW, COFFER PJ, OFFRINGA R, DAHA MR, VAN KOOTEN C: Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood (2003) 101:1439-1445.
61. DENNIS PB, JAESCHKE A, SAITOH M, FOWLER B, KOZMA SC, THOMAS G: Mammalian TOR: a homeostatic ATP sensor. Science (2001) 294 1102-1105.
62. INOKI K, ZHU T, GUAN KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 115 577-590.
63. GAO Y, ZHANG Y, ARRAZOLA P et al.: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell. Biol. (2002) 4:699-704.
64. METCALF CE: Structure-based desing of AP23573, a phosphorous-containing analog of rapamycin for anti-tumor therapy. In: American Association for Cancer Research. Orlando, Florida (2004).
65. DUMONT FJ, STARUCH MJ, KOPRAK SL, MELINO MR, SIGAL NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. (1990) 144 251-258.
66. KUO CJ, CHUNG J, FIORENTINO DF, FLANAGAN WM, BLENIS J, CRABTREE GR: Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature (1992) 358:70-73.
67. HACKSTEIN H, TANER T, ZAHORCHAK AF et al.: Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 101:4457-4463.
68. CHIANG PH, WANG L, BONHAM CA et al.: Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J. Immunol. (2004) 172 1355-1363.
69. MONTI P, MERCALLI A, LEONE BE, VALERIO DC, ALLAVENA P, PIEMONTI L: Rapamycin impairs antigen uptake of human dendritic cells. Transplantation (2003) 75:137-145.
70. ABE M, THOMSON AW: Influence of immunosuppressive drugs on dendritic cells. Transpl. Immunol. (2003) 11:357-365.
71. HONG JC, KAHAN BD: Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation (2001) 71 1579-1584.
72. EISEN H, ROSS H: Optimizing the immunosuppressive regimen in heart transplantation. J. Heart Lung Transplant. (2004) 23 S207-S213.
73. DAVIDSON J, WILKINSON A, DANTAL J et al.: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 75:SS3-SS24.
74. OBERBAUER R, KREIS H, JOHNSON RW et al.: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 76:364-370.
75. LO A, EGIDI MF, GABER LW et al.: Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation (2004) 77:1228-1235.
76. SHAFFER D, LANGONE A, NYLANDER WA, GORAL S, KIZILISIK AT, HELDERMAN JH: A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin. Transplant. (2003) 17(Suppl. 9):31-34.
77. KEOGH A, RICHARDSON M, RUYGROK P et al.: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation (2004) 110(17):2694-700.
78. CASAS-MELLEY AT, FALKENSTEIN KP, FLYNN LM, ZIEGLER VL, DUNN SP: Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr. Transplant (2004) 8:362-366.
79. ZHENG XX, SANCHEZ-FUEYO A, SHO M, DOMENIG C, SAYEGH MH, STROM TB: Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 19 503-514.
80. SANCHEZ-FUEYO A, WEBER M, DOMENIG C, STROM TB, ZHENG XX: Tracking the immunoregulatory mechanisms active during allograft tolerance. J. Immunol. (2002) 168:2274-2281.
81. KNECHTLE SJ: Combination therapy to prevent kidney transplant rejection. Phase I/II Clinical Trial (2004).
82. NATIONAL INSTITUTE OF DIABETES, DIGESTIVE AND KIDNEY DISEASES: Evaluating the use of thymoglobulin, sirolimus, and donor bone marrow with kidney transplantation patients. Phase I/II Clinical Tial (2004).
83. BERGER E, WILLIAMS DO, REINERT S, MOST AS: Sustained efficacy of percutaneous transluminal coronary angioplasty. Am. Heart J. (1986) 111:233-236.
84. AUSTIN GE, RATLIFF NB, HOLLMAN J, TABEI S, PHILLIPS DF: Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. (1985) 6:369-375.
85. JAYARAMAN T, MARKS AR: Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J. Biol. Chem. (1993) 268:25385-25388.
86. GALLO R, PADUREAN A, JAYARAMAN T et al.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 99 2164-2170.
87. MORICE MC, SERRUYS PW, SOUSA JE et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. (2002) 346 1773-1780.
88. MOSES J, LEON MB, POPMA JJ et al.: SIRIUS: a US multicenter randomized, double blind study of the Sirolimus eluting stent in de novo native coronary lesions. in Presented at the transcatheter cardiovascular therapeutics conference. Washington DC (2002).
89. TANABE K, SERRUYS PW, GRUBE E et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation (2003) 107:559-564.
90. WOODS TC, MARKS AR: Drug-eluting stents. Ann. Rev Med (2004) 55:169-178.
91. ELHENDY A, VAN DOMBURG RT, VANTRIMPONT P et al.: Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imaging. Am. J. Cardiol. (2002) 89:964-968.
92. JULIUS BK, ATTENHOFER JOST CH, SUTSCH G et al.: Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation (2000) 69:847-853.
93. EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. (2003) 349:847-858.
94. STECK PA, PERSHOUSE MA, JASSER SA et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. (1997) 15:356-362.
95. RISINGER JI, HAYES AK, BERCHUCK A, BARRETT JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. (1997) 57 4736-4738.
96. NESHAT MS, MELLINGHOFF IK, TRAN C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA (2001) 98:10314-10319.
97. PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA (2001) 98 10320-10325.
98. SHI Y, GERA J, HU L et al.: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. (2002) 62:5027-5034.
99. GERA JF, MELLINGHOFF IK, SHI Y et al.: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Mol. Chem. (2004) 279:2737-2746.
100. CHENG JQ, GODWIN AK, BELLACOSA A et al.: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA (1992) 89:9267-9271.
101. JENNE DE, REIMANN H, NEZU J et al.: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. (1998) 18:38-43.
102. HEMMINKI A, MARKIE D, TOMLINSON I et al.: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 391:184-187.
103. SHAW RJ, BARDEESY N, MANNING BD et al.: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 6:91-99.
104. HAYDON MS, GOOGE JD, SORRELLS DS, GHALI GE, LI BD: Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer (2000) 88 2803-2810.
105. SORRELLS DL, MESCHONAT C, BLACK D, LI BD: Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J. Surg. Res. (1999) 85:37-42.
106. WANG S, LLOYD RV, HUTZLER MJ et al.: Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid (2001) 11 1101-1107.
107. BERKEL HJ, TURBAT-HERRERA EA, SHI R, DE BENEDETTI A: Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol. Biomarkers Prev. (2001) 10:663-666.
108. ROSENWALD IB, CHEN JJ, WANG S, SAVAS L, LONDON IM, PULLMAN J: Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene (1999) 18 2507-2517.
109. LI BD, MCDONALD JC, NASSAR R, DE BENEDETTI A: Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann. Surg. (1998) 227:756-761; discussion 761-763.
110. CREW JP, FUGGLE S, BICKNELL R, CRANSTON DW, DE BENEDETTI A, HARRIS AL: Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer (2000) 82:161-166.
111. SCOTT PA, SMITH K, POULSOM R, DE BENEDETTI A, BICKNELL R, HARRIS AL: Differential expression of vascular endothelial growth factor mRNA versus protein isoform expression in human breast cancer and relationship to eIF-4E. Br. J. Cancer (1998) 77:2120-2128.
112. FINGAR DC, RICHARDSON CJ, TEE AR, CHEATHAM L, TSOU C, BLENIS J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. (2004) 24:200-216.
113. DILLING MB, GERMAIN GS, DUDKIN L et al.: 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem. (2002) 277:13907-13917.
114. MARTIN ME, PEREZ MI, REDONDO C, ALVAREZ MI, SALINAS M, FANDO JL: 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int. J. Biochem. Cell Biol. (2000) 32:633-642.
115. BAUER C, BRASS N, DIESINGER I, KAYSER K, GRASSER FA, MEESE E: Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int. J. Cancer (2002) 98:181-185.
116. AVDULOV S, LI S, MICHALEK V et al.: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 5:553-563.
117. RUGGERO D, MONTANARO L, MA L et al.: The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. (2004) 10:484-486.
118. SECOMBE J, PIERCE SB, EISENMAN RN: Myc: a weapon of mass destruction. Cell (2004) 117:153-156.
119. DATTA SR, DUDEK H, TAO X et al.: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 91:231-241.
120. ZHA J, HARADA H, YANG E, JOCKEL J, KORSMEYER SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell (1996) 87 619-628.
121. WENDEL HG, DE STANCHINA E, FRIDMAN JS et al.: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 428:332-337.
122. HUANG S, LIU LN, HOSOI H, DILLING MB, SHIKATA T, HOUGHTON PJ: p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. (2001) 61:3373-3381.
123. HUANG S, SHU L, DILLING M B et al.: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21 (Cip1). Mol. Cell. (2003) 11:1491-1501.